The federal government’s decision to slash $500 million in funding for mRNA vaccine research has sparked concern among health ...

GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation: London, UK Saturday, August 9, 2025, 10:00 Hrs [IST] GSK plc announces that, in connection with th ...

Federal regulators are caught between old-guard conservatives who demand continued mRNA funding, Rep. Massie's demand to ...

Kennedy’s $500M cut to mRNA funding puts startups at risk and imperils one of life sciences’ few leasing bright spots.

This week in Other Barks & Bites: the USPTO terminates 52,000 trademark applications and registrations via sanctions; the ...

An official overseeing implementation of the Make America Healthy Again agenda at the Department of Health and Human Services ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

GSK is set to receive up to $500 million and 1% royalties on future vaccine sales following the settlement of a US patent dispute between CureVac NV, Pfizer, and BioNTech SE.

In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they don't receive federal funding connected to the mRNA research cuts announced ...

US Health Secretary Robert F. Kennedy Jr. has slashed government spending on mRNA vaccine research. Experts warn it will boost global vulnerability to future pandemics.

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

"Imagine defunding penicillin research in 1943 because of rare reactions. Absurd, right?" Dr. Jerome Adams wrote on X.